gsk3174998
mAbexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2015 (NCT02528357)
Timeline
Indications
Mechanism of action
TNFSF4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk3174998
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04126200 | Phase 2 | Oct 7, 2019 | GlaxoSmithKline |
| NCT06160609 | Phase 1/Phase 2 (Phase 2) | Oct 7, 2019 | GlaxoSmithKline |
| NCT03447314 | Phase 1 | Mar 26, 2018 | GlaxoSmithKline, IQVIA |
| NCT02528357 | Phase 1 | Sep 1, 2015 | GlaxoSmithKline, Merck |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 4 | 4 | 2 | 2015 |
| IQVIA | For profit | 1 | 0 | 1 | 2018 |
| Merck | For profit | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1